GlassScriptPhysician profile
Michaela A Turner
NPI 1689934747
$1,145.24
in general payments reported to CMS, 2019-2025
22 companies · $96.99 in 2025
The $96.99 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $243 · 2022: $453 · 2023: $150 · 2024: $203 · 2025: $96.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $190.91 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $170.10 | 2021-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $163.30 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $152.15 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $54.49 | 2021-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $46.75 | 2021 | |
| Pfizer INC. | $43.64 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.97 | 2021-2024 | Trulance, Xifaxan |
| Axsome Therapeutics, INC. | $39.52 | 2022-2023 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $29.24 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.69 | 2022 | |
| Globus Medical, INC. | $27.58 | 2025 | Senza |
| Amgen INC. | $24.39 | 2021-2022 | |
| Corium, LLC | $19.61 | 2024 | Azstarys |
| Medtronic, INC. | $18.86 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $18.24 | 2025 | Nuplazid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.32 | 2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $15.94 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.13 | 2022 | |
| Paratek Pharmaceuticals, INC. | $12.90 | 2022 | |
| Eisai INC. | $12.77 | 2021 | |
| Genentech USA, INC. | $6.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.